Vident Investment Advisory LLC decreased its position in shares of Humana Inc (NYSE:HUM) by 0.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,278 shares of the insurance provider’s stock after selling 202 shares during the quarter. Vident Investment Advisory LLC’s holdings in Humana were worth $5,278,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its holdings in shares of Humana by 74.1% during the third quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock worth $664,921,000 after purchasing an additional 1,161,661 shares during the period. Wells Fargo & Company MN lifted its holdings in Humana by 11.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,842,029 shares of the insurance provider’s stock valued at $456,951,000 after acquiring an additional 188,711 shares during the period. Geode Capital Management LLC lifted its holdings in Humana by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,522,654 shares of the insurance provider’s stock valued at $376,937,000 after acquiring an additional 28,147 shares during the period. Ameriprise Financial Inc. lifted its holdings in Humana by 10.8% in the third quarter. Ameriprise Financial Inc. now owns 1,465,119 shares of the insurance provider’s stock valued at $356,960,000 after acquiring an additional 142,706 shares during the period. Finally, Acadian Asset Management LLC lifted its holdings in Humana by 3.0% in the fourth quarter. Acadian Asset Management LLC now owns 1,043,303 shares of the insurance provider’s stock valued at $258,809,000 after acquiring an additional 30,812 shares during the period. 97.85% of the stock is owned by hedge funds and other institutional investors.
Shares of Humana Inc (NYSE:HUM) opened at $271.09 on Friday. The company has a market capitalization of $37,243.61, a P/E ratio of 23.14, a PEG ratio of 1.47 and a beta of 0.95. Humana Inc has a 12-month low of $203.48 and a 12-month high of $293.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.34 earnings per share. sell-side analysts anticipate that Humana Inc will post 13.81 EPS for the current fiscal year.
Humana announced that its Board of Directors has approved a stock buyback program on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to purchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be given a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.74%. Humana’s payout ratio is 9.59%.
In related news, insider M Todoroff Christopher sold 16,389 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the completion of the sale, the insider now directly owns 13,447 shares in the company, valued at $3,676,006.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Cynthia H. Zipperle sold 1,196 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The stock was sold at an average price of $273.33, for a total value of $326,902.68. Following the sale, the senior vice president now owns 7,771 shares of the company’s stock, valued at $2,124,047.43. The disclosure for this sale can be found here. Insiders sold 41,775 shares of company stock valued at $11,169,845 over the last 90 days. Company insiders own 0.60% of the company’s stock.
A number of research analysts have issued reports on the company. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 19th. Leerink Swann boosted their price target on Humana from $280.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. JPMorgan Chase & Co. boosted their price target on Humana from $253.00 to $271.00 and gave the company a “neutral” rating in a report on Monday, February 12th. Jefferies Group raised Humana from a “hold” rating to a “buy” rating and set a $221.00 price target for the company in a report on Friday, January 12th. Finally, Credit Suisse Group raised Humana from a “neutral” rating to an “outperform” rating and decreased their price target for the company from $264.90 to $246.00 in a report on Thursday, February 8th. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $270.47.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.